These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30878952)

  • 21. Therapeutic use of the phosphate binder lanthanum carbonate.
    Barton Pai A; Conner TA; McQuade CR
    Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):71-81. PubMed ID: 19236230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
    Guo H; Zhang X; Tang S; Zhang S
    Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
    Altmann P; Barnett ME; Finn WF;
    Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastropathy associated with lanthanum phosphate deposition that was endoscopically tracked for 3 years. A case report.
    Ohno A; Miyoshi J; Tanabe H; Kusuhara M; Toki M; Chiba T; Shimoyamada H; Shibahara J; Hisamatsu T
    BMC Gastroenterol; 2020 Aug; 20(1):292. PubMed ID: 32867713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
    Keith MS; Wilson RJ; Preston P; Copley JB
    Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y; Masumoto A; Moribata M; Shigemathu T
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.
    Yamada S; Yoshida H; Taniguchi M; Tanaka S; Eriguchi M; Nakano T; Tsuruya K; Kitazono T
    Intern Med; 2012; 51(16):2097-104. PubMed ID: 22892485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extensive lanthanum deposition in the gastric mucosa: the first histopathological report.
    Makino M; Kawaguchi K; Shimojo H; Nakamura H; Nagasawa M; Kodama R
    Pathol Int; 2015 Jan; 65(1):33-7. PubMed ID: 25413959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
    Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
    J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lanthanum phosphate deposition in the gastric mucosa of patients with chronic renal failure].
    Iwamuro M; Kanzaki H; Tanaka T; Kawano S; Kawahara Y; Okada H
    Nihon Shokakibyo Gakkai Zasshi; 2016 Jul; 113(7):1216-22. PubMed ID: 27383105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease.
    Cernaro V; Calimeri S; Laudani A; Santoro D
    Ther Clin Risk Manag; 2020; 16():871-880. PubMed ID: 32982259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    St Peter WL; Wazny LD; Weinhandl ED
    Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reasons for phosphate binder discontinuation vary by binder type.
    Wang S; Anum EA; Ramakrishnan K; Alfieri T; Braunhofer P; Newsome B
    J Ren Nutr; 2014 Mar; 24(2):105-9. PubMed ID: 24462496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nano-lanthanum hydroxide, a novel phosphate binder, for treating hyperphosphatemia: A preclinical study.
    Ma Z; Yu T; Wu Y; Liu D; Zhang X; Miao X; Xing H; Li G
    Biomed Pharmacother; 2019 Mar; 111():909-916. PubMed ID: 30841470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Unexpected deposits in the upper gastrointestinal tract : When medical history matters].
    Wagener C; Schindera S; Kuntzen T; Grobholz R
    Pathologe; 2021 Mar; 42(2):235-240. PubMed ID: 33205311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
    Wilson RJ; Keith MS; Preston P; Copley JB
    Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.